Search results for "Immunogen"

showing 10 items of 226 documents

BNT162b2 Vaccine Encoding the SARS-CoV-2 P2 S Protects Transgenic hACE2 Mice against COVID-19.

2021

BNT162b2 is a highly efficacious mRNA vaccine approved to prevent COVID-19. This brief report describes the immunogenicity and anti-viral protective effect of BNT162b2 in hACE2 transgenic mice. Prime-boost immunization with BNT162b2 elicited high titers in neutralizing antibodies against SARS-CoV-2, which correlated with viral clearance and alleviated lung lesions in these mice after viral challenge.

0301 basic medicineGenetically modified mouseSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)TransgenevirusesImmunologyefficacylcsh:Medicineimmunogenicitychallenge study03 medical and health sciences0302 clinical medicineDrug DiscoveryMedicinePharmacology (medical)030212 general & internal medicinePharmacologyMessenger RNAbiologybusiness.industrySARS-CoV-2Brief ReportImmunogenicitylcsh:RCOVID-19VirologyTiter030104 developmental biologyInfectious DiseasesmRNA vaccineImmunizationbiology.proteinAntibodybusinessVaccines
researchProduct

Duodenal Bacteria From Patients With Celiac Disease and Healthy Subjects Distinctly Affect Gluten Breakdown and Immunogenicity

2016

Background & Aims Partially degraded gluten peptides from cereals trigger celiac disease (CD), an autoimmune enteropathy occurring in genetically susceptible persons. Susceptibility genes are necessary but not sufficient to induce CD, and additional environmental factors related to unfavorable alterations in the microbiota have been proposed. We investigated gluten metabolism by opportunistic pathogens and commensal duodenal bacteria and characterized the capacity of the produced peptides to activate gluten-specific T-cells from CD patients. Methods We colonized germ-free C57BL/6 mice with bacteria isolated from the small intestine of CD patients or healthy controls, selected for their in v…

0301 basic medicineGlutensDuodenumTissue transglutaminaseT-Lymphocytesdigestive systemMicrobiologyMice03 medical and health sciencesLactobacillusmedicineAnimalsHumansImmunogenetic Phenomenachemistry.chemical_classificationHepatologybiologyImmunogenicityGastroenterologynutritional and metabolic diseasesmedicine.diseasebiology.organism_classificationGlutendigestive system diseasesSmall intestineAltered Schaedler floraMice Inbred C57BLCeliac DiseaseLactobacillus030104 developmental biologymedicine.anatomical_structurechemistryBacterial TranslocationCase-Control StudiesPseudomonas aeruginosaImmunologybiology.proteinGliadinDysbiosisGastroenterology
researchProduct

ABO blood group A transferase and its codon 69 substitution enzymes synthesize FORS1 antigen of FORS blood group system

2019

AbstractHuman histo-blood group A transferase (AT) catalyzes the biosynthesis of oligosaccharide A antigen important in blood transfusion and cell/tissue/organ transplantation. This enzyme may synthesize Forssman antigen (FORS1) of the FORS blood group system when exon 3 or 4 of the AT mRNA is deleted and/or the LeuGlyGly tripeptide at codons 266–268 of AT is replaced by GlyGlyAla. The Met69Ser/Thr substitutions also confer weak Forssman glycolipid synthase (FS) activity. In this study, we prepared the human AT derivative constructs containing any of the 20 amino acids at codon 69 with and without the GlyGlyAla substitution, transfected DNA to newly generated COS1(B3GALNT1 + A4GALT) cells e…

0301 basic medicineGlycobiologylcsh:MedicineArticleABO Blood-Group System03 medical and health scienceschemistry.chemical_compound0302 clinical medicineBiosynthesisTransferasesABO blood group systemImmunogeneticsTransferaseHumansCodonlcsh:ScienceGenechemistry.chemical_classificationMultidisciplinaryMethionineImmunochemistrylcsh:RForssman antigenMolecular biologyAmino acid030104 developmental biologyEnzymechemistryAmino Acid SubstitutionAntigens SurfaceBlood Group AntigensN-Acetylgalactosaminyltransferaseslcsh:Q030217 neurology & neurosurgeryHeLa Cells
researchProduct

Immunization against Hepatitis B Surface Antigen (HBsAg) in a Cohort of Nursing Students Two Decades after Vaccination: Surprising Feedback

2019

Health-care students can be exposed to biological risks during university training. The persistence of long-term immunogenicity against hepatitis B virus (HBV) was analyzed in a cohort of nursing students two decades after primary vaccination. A total of 520 students were enrolled at the University of Palermo and were evaluated for levels of anti-HBsAg antibodies. The students were examined during the first year of their Degree Course and were checked two years later. All students with anti-HBsAg &lt

0301 basic medicineHBsAgeducationImmunologySettore MED/42 - Igiene Generale E Applicatamedicine.disease_causeArticleHealthcare students03 medical and health sciences0302 clinical medicineNursingDrug DiscoverymedicinePharmacology (medical)030212 general & internal medicinework related biological riskHBV infectionHBV vaccinationPharmacologyHepatitis B virusbusiness.industrySettore MED/44 - Medicina Del LavoroImmunogenicityAntibody titerAnti-HBs titerVaccinationTiter030104 developmental biologyInfectious DiseasesImmunizationCohortHealthcare studentbusinessVaccines
researchProduct

Role of Immunogenetics in the Outcome of HCMV Infection: Implications for Ageing

2019

The outcome of host-virus interactions is determined by a number of factors, some related to the virus, others to the host, such as environmental factors and genetic factors. Therefore, different individuals vary in their relative susceptibility to infections. Human cytomegalovirus (HCMV) is an important pathogen from a clinical point of view, as it causes significant morbidity and mortality in immunosuppressed or immunosenescent individuals, such as the transplanted patients and the elderly, respectively. It is, therefore, important to understand the mechanisms of virus infection control. In this review, we discuss recent advances in the immunobiology of HCMV-host interactions, with partic…

0301 basic medicineHuman cytomegalovirusAgingCellular immunityvirusesCytomegalovirusReviewlcsh:Chemistry0302 clinical medicineHLA AntigensGenotypeMedicineantibodieslcsh:QH301-705.5SpectroscopyimmunosenescenceImmunity CellularbiologyGeneral MedicineImmunosenescenceGMComputer Science ApplicationsKIRHLAantibodieCytomegalovirus InfectionsHost-Pathogen InteractionsAntibodyGenotypeNKCongenital cytomegalovirus infectionHuman leukocyte antigenelderlyCatalysisVirusInorganic Chemistry03 medical and health sciencesImmunogeneticsAnimalsHumansGenetic Predisposition to DiseasePhysical and Theoretical ChemistryMolecular BiologyHCMVSettore MED/04 - Patologia Generalebusiness.industryOrganic Chemistrymedicine.diseaseImmunity Humoral030104 developmental biologylcsh:Biology (General)lcsh:QD1-999Immunologybiology.proteinbusiness030215 immunology
researchProduct

Microevolution of bank voles (Myodes glareolus) at neutral and immune-related genes during multiannual dynamic cycles: consequences for Puumala hanta…

2017

ABSTRACTUnderstanding how host dynamics, including variations of population size and dispersal, may affect the epidemiology of infectious diseases through ecological and evolutionary processes is an active research area. Here we focus on a bank vole (Myodes glareolus) metapopulation surveyed in Finland between 2005 and 2009. Bank vole is the reservoir of Puumala hantavirus (PUUV), the agent of nephropathia epidemica (NE, a mild form of hemorrhagic fever with renal symptom) in humans.M glareoluspopulations experience multiannual density fluctuations that may influence the level of genetic diversity maintained in bank voles, PUUV prevalence and NE occurrence. We examine bank vole metapopulati…

0301 basic medicineMaleMyxovirus Resistance Proteins0106 biological sciencesSELECTIONPopulation geneticsPopulation DynamicsGene ExpressionPopulation geneticsNATURAL-POPULATIONPuumala virus01 natural sciencesRodent DiseasesNephropathia epidemicaFinlandGeneticsMolecular Epidemiology0303 health scienceseducation.field_of_studyRodentArvicolinaeMicroevolutionBiological EvolutionBank voleInfectious DiseasesMHC DIVERSITYHemorrhagic Fever with Renal SyndromeHost-Pathogen Interactions[SDV.IMM]Life Sciences [q-bio]/ImmunologyFemaleDisease SusceptibilityDensity fluctuationsMicrobiology (medical)Gene FlowPopulationMetapopulationBiologyMicrobiology010603 evolutionary biology03 medical and health sciencesGenetic driftGeneticsmedicineImmunogeneticsAnimalsHumansPOPULATION-STRUCTUREAdaptationeducationMolecular BiologyEcology Evolution Behavior and SystematicsDisease Reservoirs030304 developmental biologyTOLL-LIKE RECEPTORSHost-pathogen interactionPolymorphism Genetic[SDV.GEN.GPO]Life Sciences [q-bio]/Genetics/Populations and Evolution [q-bio.PE]MX2 PROTEINGenetic DriftNECROSIS-FACTOR-ALPHADENSITY-FLUCTUATIONSmedicine.diseasebiology.organism_classificationEUROPEAN ROE DEERToll-Like Receptor 4030104 developmental biologyToll-Like Receptor 7Evolutionary biology3121 General medicine internal medicine and other clinical medicineVoleRODENT HOST[SDV.EE.IEO]Life Sciences [q-bio]/Ecology environment/Symbiosis
researchProduct

Amino Acid Polymorphisms in Hla Class II Differentiate Between Thyroid and Polyglandular Autoimmunity.

2019

Abstract Context The structure of the human leucocyte antigen (HLA) peptide-binding clefts strongly contributes to monoglandular and polyglandular autoimmunity (AP). Objective To investigate the impact of amino acid polymorphisms on the peptide-binding interactions within HLA class II and its association with AP. Design Immunogenetic study. Setting Tertiary referral center for autoimmune endocrine diseases. Subjects 587 subjects with AP, autoimmune thyroid disease (AITD), type 1 diabetes (T1D), and healthy unrelated controls were typed for HLA class II. Methods Amino acids within the peptide binding cleft that are encoded by HLA class II exon 2 were listed for all codon positions in all sub…

0301 basic medicineMalemedicine.medical_specialtyEndocrinology Diabetes and MetabolismClinical Biochemistry030209 endocrinology & metabolismPeptide bindingImmunogeneticsHuman leukocyte antigenBiologymedicine.disease_causeBiochemistryAutoimmunityDiagnosis Differential03 medical and health sciencesExon0302 clinical medicineEndocrinologyInternal medicinemedicineHumansGenetic Predisposition to DiseaseAlleleAmino AcidsPolyendocrinopathies AutoimmunePolymorphism GeneticBiochemistry (medical)ThyroidHistocompatibility Antigens Class IIThyroiditis AutoimmuneAutoimmune polyendocrinopathyPrognosis030104 developmental biologyEndocrinologymedicine.anatomical_structureDiabetes Mellitus Type 1Case-Control StudiesFemaleBiomarkersFollow-Up StudiesThe Journal of clinical endocrinology and metabolism
researchProduct

Immunogenicity and Safety of Primary and Booster Vaccinations of a Fully Liquid DTaP-IPV-HB-PRP-T Hexavalent Vaccine in Healthy Infants and Toddlers …

2018

To support a fully liquid, diphtheria (D)-tetanus (T)-acellular pertussis (aP)-inactivated poliovirus (IPV)-hepatitis B (HB)-Haemophilus influenzae b (PRP-T) vaccine in Europe using a 2, 3, 4 month primary series and a booster at 11-15 months of age. Phase III, randomized, observer-blind studies in Germany and the Czech Republic. Participants who had not received HB vaccine were randomized to a 2, 3, 4 month primary series of DTaP-IPV-HB-PRP-T (group 1; N = 266) or a reconstituted DTaP-HB-IPV//PRP-T comparator (group 2; N = 263) and a booster of the same vaccine. Pneumococcal vaccine (PCV13) and rotavirus vaccine were coadministered at 2, 3, 4 months, and the booster was coadministered with…

0301 basic medicineMicrobiology (medical)MalePediatricsmedicine.medical_specialty030106 microbiologyImmunization SecondaryBooster doseAntibodies ViralDiphtheria-Tetanus-acellular Pertussis Vaccines03 medical and health sciences0302 clinical medicineImmunogenicity VaccineSuspensionsGermanyTetanus ToxoidMedicineHumansHepatitis B Vaccines030212 general & internal medicineVaccines CombinedDiphtheria-Tetanus-acellular Pertussis VaccinesImmunization ScheduleCzech RepublicHaemophilus VaccinesBooster (rocketry)business.industryDiphtheriaImmunogenicityVaccinationInfant NewbornInfantmedicine.diseaseRotavirus vaccineAntibodies BacterialVaccinationPoliovirus Vaccine InactivatedInfectious DiseasesPneumococcal vaccinePediatrics Perinatology and Child HealthFemalebusinessThe Pediatric infectious disease journal
researchProduct

Abstract CT034: A first-in-human phase I/II clinical trial assessing novel mRNA-lipoplex nanoparticles for potent melanoma immunotherapy

2017

Abstract Therapeutic vaccination with tumor antigen-encoding RNAs by local administration is currently being successfully employed in various clinical trials. Advancing from local to more efficient systemic targeting of antigen-presenting cells (APCs), we have developed pioneering RNA-lipoplex (RNA(LIP)) immunotherapeutics for intravenous application based on the employment of well-known lipid carriers without the need for functionalization of particles with molecular ligands. The novel RNA(LIP) formulation has been engineered to preserve RNA integrity after intravenous injection and physicochemically optimized for efficient uptake and expression of the encoded antigen by APCs in various ly…

0301 basic medicineOncologyCancer Researchmedicine.medical_specialtybusiness.industryImmunogenicitymedicine.medical_treatmentCancer02 engineering and technologyImmunotherapy021001 nanoscience & nanotechnologymedicine.diseaseClinical trialVaccination03 medical and health sciences030104 developmental biologyOncologyTolerabilityAntigenInternal medicinemedicineCancer vaccine0210 nano-technologybusinessCancer Research
researchProduct

2019

Abstract Type B Coxsackieviruses (CVBs) are a common cause of acute and chronic myocarditis, dilated cardiomyopathy and aseptic meningitis. However, no CVB-vaccines are available for human use. We have previously produced virus-like particles (VLPs) for CVB3 with a baculovirus-insect cell production system. Here we have explored the potential of a VLP-based vaccine targeting CVB1 and describe the production of CVB1-VLPs with a scalable VLP purification method. The developed purification method consisting of tangential flow filtration and ion exchange chromatography is compatible with industrial scale production. CVB1-VLP vaccine was treated with UV-C or formalin to study whether stability a…

0301 basic medicinePharmacologybiologyChemistryvirusesImmunogenicity030106 microbiologyCellIndustrial scalevirus diseasesAseptic meningitisAntibody levelCoxsackievirusmedicine.diseasebiology.organism_classificationcomplex mixturesVirology3. Good health03 medical and health sciences030104 developmental biologyAntibody responsemedicine.anatomical_structureVirus-like particleVirologymedicineAntiviral Research
researchProduct